Skip to content

A multi-center, Self-Paired Clinical Trial Assessing the Safety, Effectiveness, and User-Friendliness of Continuous Glucose Monitoring (CGM) Systems for Real-Time Interstitial Fluid Glucose Measurement in Patients with Diabetes Mellitus

A multi-center, Self-Paired Clinical Trial Assessing the Safety, Effectiveness, and User-Friendliness of Continuous Glucose Monitoring (CGM) Systems for Real-Time Interstitial Fluid Glucose Measurement in Patients with Diabetes Mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104589
Enrollment
Unknown
Registered
2025-06-19
Start date
2024-10-16
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

Gold Standard:Using intravenous blood glucose as the gold standard
Index test:CGM

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Age between 18 and 80 years (inclusive), regardless of sex. 2)Diagnosis of type 1 or type 2 diabetes mellitus (T1DM/T2DM) for at least 3 months, with stable vital signs. 3)Adequate venous access in the forearm for blood sampling, good compliance, and ability to complete the full clinical trial. 4)Subject or their legal guardian/caregiver possesses basic literacy skills for consent documentation. 5)Voluntary participation with written informed consent.

Exclusion criteria

Exclusion criteria: 1) Skin conditions at the wearing site (e.g., open wounds, scars, erythema, infection, or subcutaneous edema). 2) Neurological or immunological disorders, including epilepsy, cognitive impairment, immunosuppressive disorders, or systemic neurological diseases. 3) Acute diabetic complications, such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS). 4) Anticoagulant/antiplatelet therapy within 1 week prior to enrollment, bleeding tendency, or coagulopathy (APTT =1.5 × ULN). 5) Severe anemia (Hct 70%). 6) Comorbidities with life expectancy <1 year (e.g., terminal cancer, NYHA Class IV heart failure). 7) Severe circulatory impairment . 8) Planned/scheduled MRI, CT, or X-ray exposure within 15.5 days of device use. 9) Pregnancy, lactation, or planned pregnancy during the trial. 10) Severe allergies (polysensitivity to =2 allergens) or hypersensitivity to medical adhesives/disinfectants. 11) Participation in other interventional trials (medical device/drug) within:1 month for device studies, 5 half-lives of investigational drugs 12) Other conditions deemed unsuitable by the investigator.

Design outcomes

Primary

MeasureTime frame
Accuracy;Consistency;

Countries

China

Contacts

Public ContactLi Xiaoying

Zhongshan Hospital, Fudan University

ec@zs-hospital.sh.cn+86 136 5191 3857

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026